Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BRD2 | P25440 | 2/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL28778019 | 0.92 | BRD4 (0.49) | BRD4TDP1ALDH1A1L3MBTL1BRD2 | |
| SCHEMBL2876527 | 0.91 | BRD4 (0.60) | BRD4TDP1ALDH1A1L3MBTL1BRD2 | |
| SCHEMBL2873148 | 0.88 | BRD4 (0.57) | BRD4TDP1ALDH1A1L3MBTL1BRD2 | |
| Tert-Butyl Formate SCHEMBL27772038 | 0.84 | BRD4 (0.51) | BRD4TDP1ALDH1A1L3MBTL1BRD2 | |
| SCHEMBL2873486 | 0.83 | BRD4 (0.61) | BRD4ALDH1A1L3MBTL1TP53LMNA | |
| SCHEMBL13774518 | 0.82 | BRD4 (0.53) | BRD4TDP1ALDH1A1L3MBTL1BRD2 | |
| SCHEMBL5516214 | 0.79 | BRD4 (0.61) | BRD4BRD2BRD3TP53MEN1 | |
| SCHEMBL5513356 | 0.78 | BRD4 (0.60) | BRD4ALDH1A1L3MBTL1BRD2BRD3 | |
| SCHEMBL5514479 | 0.78 | BRD4 (0.62) | BRD4ALDH1A1L3MBTL1BRD2BRD3 | |
| SCHEMBL2877793 | 0.78 | BRD4 (0.60) | BRD4ALDH1A1L3MBTL1BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2066628-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008014186-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | BRD4 1328/4885TDP1 4324/4885ALDH1A1 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.